Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 6/20 | 0.60 |
| ▸ | ENPP1 | P22413 | 7/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341442 | 0.85 | EHMT2 (0.51) | PDE3AENPP1PDE10APDE3B | |
| SCHEMBL4717969 | 0.85 | EHMT2 (0.51) | PDE3AENPP1PDE10APDE3B | |
| SCHEMBL14341441 | 0.83 | PDE3A (0.43) | PDE3AENPP1PDE10APDE3B | |
| SCHEMBL5479463 | 0.83 | PDE3A (0.43) | PDE3AENPP1PDE10APDE3B | |
| SCHEMBL4717317 | 0.83 | PDE3A (0.43) | PDE3AENPP1PDE10APDE3B | |
| SCHEMBL5651020 | 0.80 | RET (0.47) | PDE3AENPP1PDE10AACHEBACE1 | |
| SCHEMBL5653867 | 0.79 | PDE10A (0.46) | PDE3AENPP1PDE10A | |
| SCHEMBL4164651 | 0.79 | PDE10A (0.46) | PDE3AENPP1PDE10A | |
| SCHEMBL4791600 | 0.79 | PDE10A (0.46) | PDE3AENPP1PDE10A | |
| SCHEMBL5653291 | 0.79 | PDE10A (0.46) | PDE3AENPP1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007103370-A2 | QUINAZOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265258-A1 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE5A, PDE7A | PDE3A 6/4885ENPP1 537/4885PDE10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.